USD 143.26
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| NBIX | 0.9 | 4 | 4.8 | 20.9 | -1.0 | 4.5 | 92.3 | 36.9 | 342.4 | 1046.1 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | NBIX |
| name | Neurocrine Biosciences, Inc. |
| price | 143.26 |
| changes percentage | 0.9442 |
| change | 1.34 |
| day low | 141.57 |
| day high | 144.82 |
| year high | 157.98 |
| year low | 110.95 |
| market cap | 14504645220 |
| price avg 50 | 130.5534 |
| price avg 200 | 132.9247 |
| exchange | NASDAQ |
| volume | 976378 |
| avg volume | 988295 |
| open | 142.85 |
| previous close | 141.92 |
| eps | 3.75 |
| pe | 38.2 |
| earnings announcement | 2025-02-05T12:00:00.000+0000 |
| shares outstanding | 101247000 |
| timestamp | 2025-01-17 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000914475 | |||
| revenue | 1887100000 | 1488700000 | 26.76 |
| gross profit | 1847400000 | 1465500000 | 26.06 |
| gross profit ratio | 0.98 | 0.98 | -0.55 |
| research and development expenses | 565000000 | 463800000 | 21.82 |
| operating expenses | 1596500000 | 1216500000 | 31.24 |
| interest income | 0 | 11200000 | -100.00 |
| interest expense | 4600000 | 7100000 | -35.21 |
| ebitda | 358000000 | 264600000 | 35.30 |
| ebitdaratio | 0.19 | 0.17 | 13.42 |
| operating income | 250900000 | 249000000 | 0.76 |
| operating income ratio | 0.13 | 0.17 | -20.51 |
| net income | 249700000 | 154500000 | 61.62 |
| net income ratio | 0.13 | 0.1 | 27.50 |
| eps | 2.56 | 1.61 | 59.01 |
Revenue Growth: revenue increased to 1,887 million in 2023 from 1,489 million in 2022 representing a change of 26.76%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 1,847 million in 2023 from 1,466 million in 2022 representing a change of 26.06%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 565 million in 2023 from 464 million in 2022 representing a change of 21.82%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 358 million in 2023 from 265 million in 2022 representing a change of 35.3%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 251 million in 2023 from 249 million in 2022 representing a change of 0.76%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 250 million in 2023 from 154 million in 2022 representing a change of 61.62%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 2.56 in 2023 from 2.56 in 2022 representing a change of 59.01%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 1,596 million in 2023 from 1,216 million in 2022 representing a change of 31.24%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000914475 | |||
| revenue | 622100000 | 590200000 | 5.40 |
| gross profit | 614100000 | 574600000 | 6.87 |
| gross profit ratio | 0.99 | 0.97 | 1.39 |
| research and development expenses | 195000000 | 184700000 | 5.58 |
| operating expenses | 430300000 | 426700000 | 0.84 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | 191300000 | 155200000 | 23.26 |
| ebitdaratio | 0.31 | 0.26 | 16.94 |
| operating income | 183800000 | 147900000 | 24.27 |
| operating income ratio | 0.3 | 0.25 | 17.90 |
| net income | 129800000 | 65000000 | 99.69 |
| net income ratio | 0.21 | 0.11 | 89.45 |
| eps | 1.28 | 0.64 | 100.00 |
Revenue Growth: revenue increased to 622 million in 2024Q3 from 590 million in 2024Q2 representing a change of 5.4%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 614 million in 2024Q3 from 575 million in 2024Q2 representing a change of 6.87%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 195 million in 2024Q3 from 185 million in 2024Q2 representing a change of 5.58%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 191 million in 2024Q3 from 155 million in 2024Q2 representing a change of 23.26%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 184 million in 2024Q3 from 148 million in 2024Q2 representing a change of 24.27%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to 1.28 in 2024Q3 from 1.28 in 2024Q2 representing a change of 100.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 430 million in 2024Q3 from 427 million in 2024Q2 representing a change of 0.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to 130 million in 2024Q3 from 65 million in 2024Q2 representing a change of 99.69%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000914475 | |||
| total assets | 3251400000 | 2368700000 | 37.27 |
| total liabilities | 1019400000 | 660900000 | 54.24 |
| total equity | 2232000000 | 1707800000 | 30.69 |
| cash and cash equivalents | 251100000 | 262900000 | -4.49 |
| short term investments | 780500000 | 726400000 | 7.45 |
| long term investments | 849400000 | 401500000 | 111.56 |
| total current assets | 1607000000 | 1453500000 | 10.56 |
| total non current assets | 1644400000 | 915200000 | 79.68 |
| total current liabilities | 654800000 | 537700000 | 21.78 |
| total non current liabilities | 364600000 | 123200000 | 195.94 |
| common stock | 100000 | 100000 | 0.00 |
| retained earnings | -157100000 | -406800000 | 61.38 |
| total debt | 428400000 | 262900000 | 62.95 |
Total Assets: Total Assets increased to 3,251 million in 2023 from 2,369 million in 2022 representing a change of 37.27%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 2,232 million in 2023 from 1,708 million in 2022 representing a change of 30.69%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 780 million in 2023 from 726 million in 2022 representing a change of 7.45%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,607 million in 2023 from 1,454 million in 2022 representing a change of 10.56%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to -157 million in 2023 from -407 million in 2022 representing a change of 61.38%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 1,019 million in 2023 from 661 million in 2022 representing a change of 54.24%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 251 million in 2023 from 263 million in 2022 representing a change of -4.49%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 655 million in 2023 from 538 million in 2022 representing a change of 21.78%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 428 million in 2023 from 263 million in 2022 representing a change of 62.95%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000914475 | |||
| total assets | 3535000000 | 3305000000 | 6.96 |
| total liabilities | 816100000 | 795800000 | 2.55 |
| total equity | 2718900000 | 2509200000 | 8.36 |
| cash and cash equivalents | 349100000 | 139700000 | 149.89 |
| short term investments | 878900000 | 899200000 | -2.26 |
| long term investments | 770600000 | 789400000 | -2.38 |
| total current assets | 1876600000 | 1669800000 | 12.38 |
| total non current assets | 1658400000 | 1635200000 | 1.42 |
| total current liabilities | 429700000 | 398500000 | 7.83 |
| total non current liabilities | 386400000 | 397299999 | -2.74 |
| common stock | 100000 | 100000 | 0.00 |
| retained earnings | 81100000 | -48700000 | 266.53 |
| total debt | 251400000 | 291600000 | -13.79 |
Total Assets: Total Assets increased to 3,535 million in 2024Q3 from 3,305 million in 2024Q2 representing a change of 6.96%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 2,719 million in 2024Q3 from 2,509 million in 2024Q2 representing a change of 8.36%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 349 million in 2024Q3 from 140 million in 2024Q2 representing a change of 149.89%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,877 million in 2024Q3 from 1,670 million in 2024Q2 representing a change of 12.38%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 81 million in 2024Q3 from -49 million in 2024Q2 representing a change of 266.53%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 251 million in 2024Q3 from 292 million in 2024Q2 representing a change of -13.79%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 816 million in 2024Q3 from 796 million in 2024Q2 representing a change of 2.55%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 879 million in 2024Q3 from 899 million in 2024Q2 representing a change of -2.26%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 430 million in 2024Q3 from 398 million in 2024Q2 representing a change of 7.83%. This indicates a higher short-term debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000914475 | |||
| net change in cash | -11600000 | -73300000 | 84.17 |
| operating cash flow | 389900000 | 339400000 | 14.88 |
| free cash flow | 361600000 | 322900000 | 11.99 |
| capital expenditure | -28300000 | -16500000 | -71.52 |
| depreciation and amortization | 21300000 | 15600000 | 36.54 |
| deferred income tax | -56700000 | 19100000 | -396.86 |
| stock based compensation | 194300000 | 173100000 | 12.25 |
| accounts payables | 64300000 | 114600000 | -43.89 |
| inventory | 5400000 | -2600000 | 307.69 |
| acquisitions net | 0 | -42700000 | 100.00 |
| investments in property plant and equipment | -28300000 | -16500000 | -71.52 |
| net cash used for investing activites | -467100000 | -177100000 | -163.75 |
| debt repayment | 0 | -279000000 | 100.00 |
| common stock issued | 65300000 | 44700000 | 46.09 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 65300000 | -234300000 | 127.87 |
| cash at end of period | 259100000 | 270700000 | -4.29 |
| accounts receivables | -89300000 | -162200000 | 44.94 |
| cash at beginning of period | 270700000 | 344000000 | -21.31 |
Net Change in Cash: Net Change in Cash increased to -12 million in 2023 from -73 million in 2022 representing a change of 84.17%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 390 million in 2023 from 339 million in 2022 representing a change of 14.88%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 362 million in 2023 from 323 million in 2022 representing a change of 11.99%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -28 million in 2023 from -16 million in 2022 representing a change of -71.52%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 64 million in 2023 from 115 million in 2022 representing a change of -43.89%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Stock-Based Compensation: Stock-Based Compensation increased to 194 million in 2023 from 173 million in 2022 representing a change of 12.25%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -89 in 2023 from -162 million in 2022 representing a change of 44.94%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000914475 | |||
| operating cash flow | 158000000 | 64599999 | 144.58 |
| free cash flow | 149900000 | 52999999 | 182.83 |
| capital expenditure | -8100000 | -11600000 | 30.17 |
| depreciation and amortization | 6500000 | 7300000 | -10.96 |
| deferred income tax | -34900000 | -41300000 | 15.50 |
| stock based compensation | 41500000 | 43100000 | -3.71 |
| accounts receivables | -12900000 | -17600000 | 26.70 |
| accounts payables | 39400000 | -59500000 | 166.22 |
| inventory | -3300000 | -5300000 | 37.74 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -8100000 | -11600000 | 30.17 |
| net cash used for investing activites | 24700000 | -28200000 | 187.59 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 26400000 | 15800000 | 67.09 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 26400000 | -293000000 | 109.01 |
| net change in cash | 217400000 | -256600000 | 184.72 |
| cash at end of period | 357100000 | 139700000 | 155.62 |
| cash at beginning of period | 139700000 | 396300000 | -64.75 |
Net Change in Cash: Net Change in Cash increased to 217 million in 2024Q3 from -257 million in 2024Q2 representing a change of 184.72%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 158 million in 2024Q3 from 65 million in 2024Q2 representing a change of 144.58%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 150 million in 2024Q3 from 53 million in 2024Q2 representing a change of 182.83%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 42 million in 2024Q3 from 43 million in 2024Q2 representing a change of -3.71%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 39 million in 2024Q3 from 60 million in 2024Q2 representing a change of 166.22%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -8 million in 2024Q3 from -12 million in 2024Q2 representing a change of 30.17%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -35 million in 2024Q3 from -41 million in 2024Q2 representing a change of 15.5%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to -13 in 2024Q3 from -18 million in 2024Q2 representing a change of 26.7%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 19.32 | 15.54 | 24.30 |
| net income per share | 2.56 | 1.61 | 58.48 |
| operating cash flow per share | 3.99 | 3.54 | 12.65 |
| free cash flow per share | 3.7 | 3.37 | 9.81 |
| cash per share | 10.56 | 10.33 | 2.25 |
| book value per share | 22.85 | 17.83 | 28.15 |
| tangible book value per share | 22.48 | 17.44 | 28.92 |
| shareholders equity per share | 22.85 | 17.83 | 28.15 |
| interest debt per share | 4.43 | 2.82 | 57.25 |
| market cap | 12872952000 | 11442352000 | 12.50 |
| enterprise value | 13050252000 | 11442352000 | 14.05 |
| pe ratio | 51.55 | 74.06 | -30.39 |
| price to sales ratio | 6.82 | 7.69 | -11.25 |
| pocfratio | 33.02 | 33.71 | -2.07 |
| pfcf ratio | 35.6 | 35.44 | 0.46 |
| pb ratio | 5.77 | 6.7 | -13.92 |
| ptb ratio | 5.77 | 6.7 | -13.92 |
| ev to sales | 6.92 | 7.69 | -10.03 |
| enterprise value over ebitda | 36.45 | 43.24 | -15.70 |
| ev to operating cash flow | 33.47 | 33.71 | -0.72 |
| ev to free cash flow | 36.09 | 35.44 | 1.85 |
| earnings yield | 0.02 | 0.01 | 43.66 |
| free cash flow yield | 0.03 | 0.03 | -0.46 |
| debt to equity | 0.19 | 0.15 | 24.68 |
| debt to assets | 0.13 | 0.11 | 18.71 |
| net debt to ebitda | 0.5 | 0 | NaN |
| current ratio | 2.45 | 2.7 | -9.21 |
| interest coverage | 54.54 | 35.07 | 55.53 |
| income quality | 1.56 | 2.2 | -28.92 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.3 | 0.31 | -3.90 |
| intangibles to total assets | 0.01 | 0.02 | -30.48 |
| capex to operating cash flow | 0.07 | 0.05 | 49.30 |
| capex to revenue | 0.01 | 0.01 | 35.31 |
| capex to depreciation | 1.33 | 1.06 | 25.62 |
| stock based compensation to revenue | 0.1 | 0.12 | -11.45 |
| graham number | 36.25 | 25.43 | 42.51 |
| roic | 0.07 | 0.09 | -24.16 |
| return on tangible assets | 0.08 | 0.07 | 17.17 |
| graham net net | 3.69 | 6.35 | -41.85 |
| working capital | 952200000 | 915800000 | 3.97 |
| tangible asset value | 2196500000 | 1670600000 | 31.48 |
| net current asset value | 587600000 | 792600000 | -25.86 |
| invested capital | 1335000000 | 1098600000 | 21.52 |
| average receivables | 394650000 | 267750000 | 47.39 |
| average payables | 88100000 | 59400000 | 48.32 |
| average inventory | 36700000 | 32800000 | 11.89 |
| days sales outstanding | 84.97 | 85.81 | -0.98 |
| days payables outstanding | 1001.22 | 1058.81 | -5.44 |
| days of inventory on hand | 352.13 | 552.22 | -36.23 |
| receivables turnover | 4.3 | 4.25 | 0.99 |
| payables turnover | 0.36 | 0.34 | 5.75 |
| inventory turnover | 1.04 | 0.66 | 56.82 |
| roe | 0.11 | 0.09 | 23.66 |
| capex per share | 0.29 | 0.17 | 68.18 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 51.55 on 2023-12-31 from 74.06 on 2022-12-31, representing a change of -30.39%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.45 on 2023-12-31 from 2.70 on 2022-12-31, representing a change of -9.21%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.19 on 2023-12-31 from 0.15 on 2022-12-31, representing a change of 24.68%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| NBIX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 6.15 | 5.86 | 5.09 |
| net income per share | 1.28 | 0.64 | 99.10 |
| operating cash flow per share | 1.56 | 0.64 | 143.86 |
| free cash flow per share | 1.48 | 0.53 | 181.99 |
| cash per share | 12.15 | 10.31 | 17.85 |
| book value per share | 26.89 | 24.89 | 8.04 |
| tangible book value per share | 26.55 | 24.56 | 8.11 |
| shareholders equity per share | 26.89 | 24.89 | 8.04 |
| interest debt per share | 2.49 | 2.89 | -14.04 |
| market cap | 11648742000 | 14123088000.0 | -17.52 |
| enterprise value | 11551042000 | 14274988000.0 | -19.08 |
| pe ratio | 22.44 | 54.32 | -58.70 |
| price to sales ratio | 18.72 | 23.93 | -21.75 |
| pocfratio | 73.73 | 218.62 | -66.28 |
| pfcf ratio | 77.71 | 266.47 | -70.84 |
| pb ratio | 4.28 | 5.63 | -23.88 |
| ptb ratio | 4.28 | 5.63 | -23.88 |
| ev to sales | 18.57 | 24.19 | -23.23 |
| enterprise value over ebitda | 60.38 | 91.98 | -34.35 |
| ev to operating cash flow | 73.11 | 220.98 | -66.92 |
| ev to free cash flow | 77.06 | 269.34 | -71.39 |
| earnings yield | 0.01 | 0.0 | 142.11 |
| free cash flow yield | 0.01 | 0.0 | 242.91 |
| debt to equity | 0.09 | 0.12 | -20.44 |
| debt to assets | 0.07 | 0.09 | -19.40 |
| net debt to ebitda | -0.51 | 0.98 | -152.18 |
| current ratio | 4.37 | 4.19 | 4.22 |
| interest coverage | 0 | 0 | NaN |
| income quality | 1.22 | 0.99 | 22.48 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.31 | 0.31 | 0.16 |
| intangibles to total assets | 0.01 | 0.01 | -3.72 |
| capex to operating cash flow | 0.05 | 0.18 | -71.45 |
| capex to revenue | 0.01 | 0.02 | -33.75 |
| capex to depreciation | 1.25 | 1.59 | -21.58 |
| stock based compensation to revenue | 0.07 | 0.07 | -8.65 |
| graham number | 27.87 | 19.0 | 46.66 |
| roic | 0.04 | 0.03 | 21.82 |
| return on tangible assets | 0.04 | 0.02 | 86.63 |
| graham net net | 7.87 | 6.11 | 28.88 |
| working capital | 1446900000 | 1271300000 | 13.81 |
| tangible asset value | 2684400000 | 2475700000 | 8.43 |
| net current asset value | 1060500000 | 874000000 | 21.34 |
| invested capital | 1818700000 | 1647800000 | 10.37 |
| average receivables | 474650000 | 459450000 | 3.31 |
| average payables | 101450000 | 97250000 | 4.32 |
| average inventory | 44150000 | 39850000 | 10.79 |
| days sales outstanding | 69.6 | 71.4 | -2.51 |
| days payables outstanding | 1076.62 | 618.46 | 74.08 |
| days of inventory on hand | 515.25 | 245.19 | 110.14 |
| receivables turnover | 1.29 | 1.26 | 2.58 |
| payables turnover | 0.08 | 0.15 | -42.56 |
| inventory turnover | 0.17 | 0.37 | -52.41 |
| roe | 0.05 | 0.03 | 84.29 |
| capex per share | 0.08 | 0.12 | -30.38 |
ROE: Return on Equity (ROE) increased to 0.05 on 2024-09-30 Q3 from 0.03 on 2024-06-30 Q2, representing a change of 84.29%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 22.44 on 2024-09-30 Q3 from 54.32 on 2024-06-30 Q2, representing a change of -58.70%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 4.37 on 2024-09-30 Q3 from 4.19 on 2024-06-30 Q2, representing a change of 4.22%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.09 on 2024-09-30 Q3 from 0.12 on 2024-06-30 Q2, representing a change of -20.44%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 229.65 which is higher than current price 143.26, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-08 08:30:00
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable lower, more physiologic GC dosing. The publication appears in Expert Review of Endocrinology & Metabolism.
Sentiment: Neutral
Publish Date: 2025-01-06 16:01:00
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m.
Sentiment: Positive
Publish Date: 2024-12-20 12:19:52
BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices, which it highlights were significantly higher than previous modeled. BofA continues to assume the congenital adrenal hyperplasia launch will be more of a 2H25 event given new-to-market restrictions from commercial payors, but notes that Neurocrine has pledged to offer a free goods program to allow endocrinologists to get familiar with Crenessity's clinical profile.
Sentiment: Positive
Publish Date: 2024-12-20 08:00:00
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).
Sentiment: Positive
Publish Date: 2024-12-18 10:11:35
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transformative opportunity. Peak sales are estimated at $1.47 billion by 2030. Neurocrine's pipeline includes five Phase 1, six Phase 2, and two Phase 3 programs, diversifying future growth opportunities.
Sentiment: Positive
Publish Date: 2024-12-13 19:00:47
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder Drug appeared first on Investor's Business Daily.
Sentiment: Positive
Publish Date: 2024-12-13 18:55:00
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Sentiment: Positive
Publish Date: 2024-12-13 17:50:23
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.
Sentiment: Neutral
Publish Date: 2024-11-26 16:01:00
The 7th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at: The 7th Annual Evercore HealthCONx Conference at 10:50 a.m.
Sentiment: Positive
Publish Date: 2024-11-08 11:02:07
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company with significant growth potential that it is. Ingrezza continues to deliver strong growth and cash flows for the company, and crinecerfont will be launched in early 2025.
Sentiment: Positive
Publish Date: 2024-11-07 08:30:00
Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of INGREZZA® (valbenazine) capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores.
Sentiment: Neutral
Publish Date: 2024-11-05 16:01:00
2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the 2024 UBS Global Healthcare Conference at 1:15 p.m.
Sentiment: Positive
Publish Date: 2024-11-04 08:30:00
Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA® (valbenazine) capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice.
Sentiment: Positive
Publish Date: 2024-11-04 08:25:00
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA® (valbenazine) capsules treatment. This research, "Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment" (Poster #98), was shared at the 2024 Psych Congress in Boston.
Sentiment: Positive
Publish Date: 2024-10-30 15:11:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Todd Tushla - Vice President of Investor Relations Conference Call Participants Chris Shibutani - Goldman Sachs Paul Matteis - Stifel David Ansellem - Piper Sandler Phoebe Tan - Jefferies Tazeen Ahmad - Bank of America Securities Jay Olson - Oppenheimer Ash Verma - UBS Philip Nadeau - TD Cowen Anupam Rama - J.P. Morgan Evan Seigerman - BMO Capital Markets Cory Kasimov - Evercore ISI Carter Gould - Barclays Mohit Bansal - Wells Fargo Marc Goodman - Leerink Partners Myles Minter - William Blair Michael Riad - Morgan Stanley Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Uy Ear - Mizuho Securities Ami Fadia - Needham Operator Good day, everyone and welcome to Neurocrine Biosciences' reports Third Quarter Results.
Sentiment: Positive
Publish Date: 2024-10-30 10:35:46
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sentiment: Positive
Publish Date: 2024-10-30 09:16:23
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-30 07:00:00
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications, FDA Priority Review for crinecerfont in congenital adrenal hyperplasia, a deep neuroscience focused pipeline and a strong balance sheet, we are confident in our ability to help more patients than ever before," said Kyle W.
Sentiment: Positive
Publish Date: 2024-10-23 11:07:13
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
